Showing results (201-210 of 237) with videos related to
Sort By:
Pageof 24
Breast Cancer Research and Treatment|February 24, 2001
Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancerP E Goss, K Strasser, R Marques, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials GroupC A Townsley, K Chi, D S Ernst, et al.Proceedings of the National Academy of Sciences of the United States of America|February 26, 2020
Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupusRishi R Goel, Xinghao Wang, Liam J O'Neil, et al.Current Oncology (Toronto, Ont.)|August 25, 2015
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014E Tsvetkova, S Sud, N Aucoin, et al.The American Surgeon|August 28, 2025
Neoadjuvant Chemoradiation Does Not Improve Outcomes for Patients Undergoing Resection for Upper Rectal Cancer: A US Rectal Cancer Consortium AnalysisCaroline R Goel, Christina M Gozza, Adriana C Gamboa, et al.Current Oncology (Toronto, Ont.)|August 19, 2016
Corrigendum: Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014E Tsvetkova, S Sud, N Aucoin, et al.Proceedings of the National Academy of Sciences of the United States of America|November 23, 2019
Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosusPragnesh Mistry, Shuichiro Nakabo, Liam O'Neil, et al.Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.Iscience|January 3, 2023
An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cellsAlexandre Nicolas, Gérémy Sannier, Mathieu Dubé, et al.Nature Immunology|October 21, 2022
Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigeneticsJosephine R Giles, Shin Foong Ngiow, Sasikanth Manne, et al.Pageof 24